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clinicians. However, the limited available evidence sug-
gests that osteoporosis treatment does reduce fracture risk 
in obesity and T2DM with generally similar efficacy to 
other patients.
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Obesity, Type 2 Diabetes and Bone
Obesity is a major and growing public health problem; for 
example, in the UK, 40% of adults will be obese by 2025 
[1]. Obesity is the most important risk factor for type 2 dia-
betes (T2DM), and the global prevalence of T2DM is likely 
to be 592 million by 2035 [2]. As the population ages, the 
burden of osteoporosis and fragility fracture also increases. 
Obesity and T2DM have effects on fracture risk, and frac-
tures in T2DM are associated with greater morbidity than 
in the general population. Understanding how to assess and 
treat fracture risk in these groups is important for health 
care planning and individual patients. Additionally, the 
study of the mechanisms of action of obesity and T2DM on 
bone has already offered insights that may be applicable in 
the broader study of osteoporosis, such as the effects of adi-
pokines on bone cells and the effects of collagen glycation 
on material properties of bone. There are some similari-
ties in the effect of obesity and T2DM on bone, but some 
important differences such as cortical porosity and collagen 
glycation.
In this review, we describe the effects of obesity and 
T2DM on fracture risk and discuss possible mechanisms of 
their effects. We also consider the validity of existing frac-
ture risk prediction tools and efficacy of osteoporosis treat-
ment in these patient groups.
Abstract In an increasingly obese and ageing population, 
type 2 diabetes (T2DM) and osteoporotic fracture are major 
public health concerns. Understanding how obesity and 
type 2 diabetes modulate fracture risk is important to iden-
tify and treat people at risk of fracture. Additionally, the 
study of the mechanisms of action of obesity and T2DM on 
bone has already offered insights that may be applicable to 
osteoporosis in the general population. Most available evi-
dence indicates lower risk of proximal femur and vertebral 
fracture in obese adults. However the risk of some frac-
tures (proximal humerus, femur and ankle) is higher, and 
a significant number fractures occur in obese people. BMI 
is positively associated with BMD and the mechanisms of 
this association in vivo may include increased loading, adi-
pokines such as leptin, and higher aromatase activity. How-
ever, some fat depots could have negative effects on bone; 
cytokines from visceral fat are pro-resorptive and high 
intramuscular fat content is associated with poorer muscle 
function, attenuating loading effects and increasing falls 
risk. T2DM is also associated with higher bone mineral 
density (BMD), but increased overall and hip fracture risk. 
There are some similarities between bone in obesity and 
T2DM, but T2DM seems to have additional harmful effects 
and emerging evidence suggests that glycation of collagen 
may be an important factor. Higher BMD but higher frac-
ture risk presents challenges in fracture prediction in obe-
sity and T2DM. Dual energy X-ray absorptiometry under-
estimates risk, standard clinical risk factors may not capture 
all relevant information, and risk is under-recognised by 
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Obesity, Fracture and BMD
Most of the available evidence supports a lower risk of 
proximal femur and vertebral fracture in obese adults 
[3]. However, fracture risk in obesity is not lower at all 
skeletal sites; the risk of some non-spine fractures includ-
ing proximal humerus (RR 1.28), upper leg (OR 1.7) and 
ankle fracture (OR 1.5) is higher [4, 5]. A large number 
of low-trauma fractures occur in overweight and obese 
men and women, and the prevalence of low-trauma 
fractures is similar in obese and non-obese women [6]. 
Therefore, obesity is not entirely protective against frac-
ture, and there are some site-specific effects on fracture.
There is a positive association between body mass 
index (BMI) and bone mineral density (BMD) [7]. BMD 
by dual-energy X-ray absorptiometry (DXA) is higher in 
obese people, but higher BMI and soft tissue thickness 
cause error in DXA measurement [8] through assump-
tions about abdominal thickness and beam hardening 
effects. However, other quantitative imaging methods 
(CT and ultrasound) also support higher BMD by DXA 
(although other methods are also subject to some influ-
ence from surrounding soft tissue). Calcaneus bone stiff-
ness by ultrasound is greater in obesity [9] and by high-
resolution peripheral quantitative computed tomography 
(HR-pQCT), obese adults have higher BMD, higher cor-
tical BMD, higher trabecular BMD and greater trabecu-
lar number at the distal radius and distal tibia [10, 11]. 
Radius and tibia strength estimated by finite element 
analysis from HR-pQCT is greater in obesity than in nor-
mal weight controls [10]. Therefore, BMD probably is 
truly higher in obesity, and there is no site-specific BMD 
deficit to explain the site-specific fracture risk.
It is possible that even if BMD increases in response to 
obesity, the capacity for increase is limited and eventually 
the load-to-strength ratio rises far enough to cause frac-
ture in low-trauma injuries. The increase in radius and tibia 
strength by HR-pQCT in obesity is proportionally less than 
the increase in BMI [11]. At the hip, by QCT and DXA, 
obese people have favourable features for bone strength, 
but the load-to-strength ratio is greater than normal weight 
controls [12, 13]. Greater soft-tissue thickness over the 
lateral hip dissipates fall impact, and so may continue to 
protect against hip fracture at high body weight even when 
load-to-strength ratio is exceeded [12, 14]. Intramuscular 
fat content is increased in obesity, and may be associated 
with poorer muscle function and increased fracture risk 
(‘dynapenic obesity’) [15, 16]. Poorer muscle function 
could increase falls and injury when falling, and there are 
data showing an excess of falls in obese people [17].
Thus, although BMD is higher in obesity, it may not 
be increased sufficiently to resist the greater forces acting 
when obese people fall. Non-bone factors such as muscle 
function and soft tissue thickness should also be considered 
as contributory and protective factors.
Mechanisms of Action of Obesity on Bone
Some insight into how obesity may exert effects on bone 
can be obtained from biochemical markers of bone turno-
ver. Biochemical markers are lower in obesity than in nor-
mal weight [18], but the difference in resorption markers 
may be greater than the difference in formation markers. 
This results in a higher uncoupling index in obesity, sug-
gesting positive bone balance which helps to maintain bone 
mass in adulthood and with ageing [10]. Menopause causes 
a rapid increase in bone turnover, with net higher bone 
resorption and negative bone balance leading to bone loss. 
Higher body weight is associated with slower menopausal 
bone loss [19] consistent with a tendency towards positive 
bone balance in obesity.
One possible mechanism for higher BMD in obesity 
is increased mechanical loading and strain. Obese adults 
have increased body fat mass, but also increased lean mass, 
so passive loading and muscle-induced strain may have 
effects on bone modelling, density and geometry. However, 
impaired muscle function due to intramuscular fat accu-
mulation could attenuate the positive effects of increased 
muscle mass on bone. If the dominant mechanism acting to 
increase BMD were physical loading, an increase in bone 
size by periosteal apposition might be expected. Hip cross-
sectional area by DXA and QCT is increased in obesity 
[12, 13], but bone size at the radius and tibia by HR-pQCT 
does not differ between obese and normal weight controls 
[10]. Therefore, loading probably does not explain all of 
the action of obesity on bone.
Obesity has effects on a number of hormones known 
to act on bone, and so may act on bone through endocrine 
pathways. Adipocytes produce endocrine factors shown to 
influence bone cell number and activity. Leptin is produced 
by adipocytes, and circulating leptin levels reflect body fat 
mass with a primary role to regulate long-term energy bal-
ance by signalling satiety in the hypothalamus and reducing 
food intake. Circulating leptin acts on bone cells directly 
to increase bone formation [20], but when acting through 
the hypothalamus, it may inhibit bone formation through 
increased activation of the sympathetic nervous system 
[21]. The evidence from clinical human studies suggests 
that the dominant effect in vivo is probably the peripheral 
action to increase BMD [22]. Adiponectin is secreted in 
inverse proportion to fat mass, and has roles in the regula-
tion of glucose and lipid metabolism. In humans, circulat-
ing adiponectin levels are inversely related to BMD [23]. 
Osteoclasts and osteoblasts express adiponectin receptors, 
and there is some experimental evidence that adiponectin 
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could modulate RANK/RANK-ligand/OPG signalling [24]. 
Similarly to leptin, mouse studies suggest that adiponec-
tin may also signal through the central nervous system to 
regulate bone turnover through autonomic innervation [25]. 
However, the dominant mechanism through which it acts 
on the skeleton in obese humans in  vivo is not yet clear. 
Adipocytes express aromatase, and aromatisation of andro-
gens is the main source of oestrogen in postmenopausal 
women and men. High fat mass is associated with higher 
circulating estradiol, and so aromatase activity is likely to 
contribute to positive effects of fat on bone, particularly in 
postmenopausal women [26].
Pancreatic and gut hormone secretion is altered in obe-
sity and may influence bone metabolism. Insulin, amylin 
and preptin are increased in obesity, and may have direct 
effects on bone cells to increase bone formation and 
decrease resorption. Insulin may also have indirect posi-
tive effects on bone by decreasing hepatic sex-hormone 
binding globulin production, increasing bioavailability of 
oestrogen and androgens. Ghrelin, gastric inhibitory pol-
ypeptide (GIP) and glucagon-like peptide 2 (GLP-2) have 
direct and indirect effects on bone metabolism, driven 
by the acute response to food intake and more long-term 
energy balance [27].
Serum 25-hydroxy vitamin D (25OHD) is lower in 
obesity than normal weight controls, but this is likely to 
reflect greater volume of distribution (into fat, muscle 
and extracellular fluid). Therefore, serum 25OHD may 
not indicate low whole-body vitamin D status in obesity, 
and it does not seem to be associated with lower BMD or 
higher bone turnover. It is possible that the lower vita-
min D in obesity would adversely affect BMD, but that 
the other positive effects of obesity on BMD are domi-
nant [28].
Not all fat is the same, and some fat depots could have 
negative effects on bone (Fig.  1). Subcutaneous and vis-
ceral fat have different metabolic profiles, and pro-inflam-
matory cytokines from visceral fat such as interleukin-6 
(IL-6) and tumour necrosis factor alpha (TNF-α) increase 
bone resorption, so may have harmful effects on BMD [29]. 
In support of adverse actions, greater central and visceral 
adiposity is associated with lower BMD and some adverse 
microstructural features from bone biopsy and HR-pQCT 
but the relationship may vary with age and gender [30–32].
Fig. 1  Fat depot actions on bone in obesity
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Fracture Risk Assessment and Osteoporosis 
Treatment in Obesity
Fracture risk assessment in clinical practice uses bone 
densitometry by DXA and clinical risk factors. This offers 
some challenges in obesity—the precision of DXA meas-
urements is reduced in obesity due to effects of soft tis-
sue thickness [8]. Also, because fracture pattern differs 
between obese and normal weight groups, and we do not 
yet fully understand the cause of fractures in obesity, the 
usual fracture prediction tools might not be expected to 
perform so well. However, FRAX (with and without BMD) 
predicted hip and major osteoporotic fracture with similar 
accuracy in obese and non-obese postmenopausal women 
in the Study of Osteoporotic Fractures [33].
Most currently used drugs for osteoporosis are anti-
resorptive. Because bone turnover and bone resorption are 
already reduced in obesity, the question has been raised 
whether anti-resorptive treatment is effective for fracture 
prevention in obesity. The key clinical trials of bisphospho-
nates did not include large numbers of obese people, but 
there are some available data. In the Horizon trial, 3 years 
of zoledronic acid decreased vertebral fracture more in 
postmenopausal women with BMI above 25  kg/m2 than 
women with BMI below 25 kg/m2 [34]. Non-vertebral frac-
ture reduction did not differ by BMI. In the Freedom trial, 
with  3  years of denosumab, vertebral fracture risk reduc-
tion was independent of BMI, but non-vertebral fracture 
reduction was not significant in women with BMI above 
25 kg/m2 [35].
Type 2 Diabetes, Fracture and BMD
A number of meta-analyses have reported an increase in 
the risk of fractures in type 2 diabetes (T2DM) [36–40]. 
There is a 1.3- to 2.1-fold increased risk of hip fracture 
[36, 37, 39, 40] and 1.2-fold increased risk of other frac-
tures [36, 37], but vertebral fracture risk does not seem to 
be increased [37, 40] (Table  1). The size of the fracture 
risk increase may be modest, but it is important to recog-
nise that after fracture, patients with diabetes have greater 
mortality, develop more complications (such as renal 
impairment and cardiac problems) and recover less well 
than non-diabetic patients [41, 42].
Although fracture risk is higher, BMD is increased 
in T2DM (lumbar spine Z-score + 0.41, total hip 
Z-score + 0.27) [37]. Nearly all people with T2DM are 
obese, and so the higher BMD in T2DM is probably due to 
similar mechanisms as those acting in non-diabetic obese 
people. In addition, high circulating insulin could increase 
osteoblast activity and bone formation [43]. The increase in 
foot and ankle fractures is consistent with the pattern seen 
in obesity, but the increase in hip fracture risk is discrepant 
between T2DM and non-diabetic obese, so additional fac-
tors may be acting to increase bone fragility in T2DM.
Microarchitecture studies with HR-pQCT suggest a cor-
tical strength deficit in T2DM. There is decreased cortical 
thickness and volumetric BMD (vBMD), with increased 
cortical porosity and pore size in T2DM [44] patients with 
microvascular disease (retinopathy, neuropathy or nephrop-
athy). These changes are associated with decreased bone 
strength by finite element analysis [44, 45] and are greater 
in T2DM patients with previous fractures [46], suggesting 
that they may be clinically significant contributors to frac-
ture risk.
Mechanisms of Action of T2DM on Bone
Bone turnover markers studies in diabetes have had some 
conflicting results, but the most consistent finding is that 
markers of resorption (C-terminal cross-linking telopeptide 
of type I collagen (CTX), N-terminal cross-linking telopep-
tide of type I collagen (NTX)) and formation (procollagen 
type I N propeptide (P1NP), osteocalcin) are reduced [47, 
48]. Methodological studies have excluded a direct effect 
of glucose in the measurements [48], so the bone turnover 
markers probably do reflect a true biological effect. Histo-
morphometry in T2D shows decrease in bone volume, 
osteoid volume, thickness and osteoblast surface, and poor 
uptake of label indicating reduced bone formation [49, 50] 
consistent with lower turnover from biochemical markers.
One important factor which may contribute to bone 
fragility in T2DM is post-translational glycation of colla-
gen in bone matrix. Enzymatic cross-linking of collagen 
maintains the strength of normal bone matrix because the 
Table 1  Risk of hip, spine and 
other any fractures in T2DM 
according to meta-analyses
*Statistically significant increase in the risk
Study Hip fractures Spine fractures Other fractures
Janghorbani [32] 1.7 (1.3–2.2)* 1.2 (0.7–2.2) Any fracture 1.2 (1.01–1.5)*
Vestergaard [33] 1.38 (1.25–1.53)* 0.93 (0.63–1.37) Any fractures 1.19 (1.11–1.27)*
Fan [35] 2.07 (1.83–2.33)* – –
Dytfeld [36] 1.26 (1.07–1.57)* 1.13 (0.94–1.37) –
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collagen matrix confers toughness, allowing the bone to 
endure plastic strain without breaking. Increasing numbers 
of cross-links reduces the plasticity of the matrix, and the 
bone breaks at lower strain. Older collagen has more cross-
links and less plasticity. Exposure to high glucose levels 
promotes glycation of proteins [advanced glycation end 
products (AGEs)]. In collagen, AGEs lead to non-enzy-
matic cross-linking [51], and so could decrease plasticity 
and bone material strength [52]. Higher urine pentosidine 
(a marker of AGEs) is associated with higher vertebral 
fracture risk in post-menopausal non-diabetic women [53].
Bone material strength can be evaluated in vivo by ref-
erence point indentation (Osteoprobe). By this method, 
material strength is 10% lower in T2DM than matched con-
trols. The difference persists after correction for BMI and 
is correlated with average HbA1c [54]. Indirect measure-
ment of AGEs using skin auto fluorescence explains 26% 
of the reduced bone strength by indentation, and is asso-
ciated with lower P1NP in patients with T2D [55]. There-
fore, there is some evidence for an association of glucose 
exposure with poor bone material quality in T2DM, and 
collagen glycation is a plausible contributor to increased 
fracture risk.
Particularly for foot and ankle fracture, it is possible that 
neuropathy and vasculopathy in T2DM could have effects 
on bone cell function or bone material properties. Symp-
thetic tone contributes to the regulation of bone turnover, 
and the extreme example of Charcot foot demonstrates the 
potential for bone to dysfunction when normal sensory 
and autonomic innervation is lost. However, these factors 
have not yet been investigated in the context of diabetes 
and fracture. Besides the intrinsic bone properties, other 
factors could increase the risk of fractures in T2DM. Poor 
metabolic control, hypoglycaemia and neuropathy increase 
falls risk [56, 57], and in meta-analysis, hypoglycaemia 
was associated with fracture (OR 1.92) [58]. However, 
increased fracture risk persists after correction for falls 
[59].
Diabetes treatment may also modulate fracture risk [60]. 
Metformin and sulfonylureas have neutral or slightly pro-
tective associations with fracture risk [60, 61]. It is possible 
that metformin increases osteoblast activity through Runt-
related transcription factor 2 (Runx2) signalling. Thiazoli-
dinediones (TZDs, glitazones) activate peroxisome prolif-
erator-activated receptor gamma (PPARγ) which decreases 
insulin resistance. Activation of PPARγ suppresses IGF-1 
expression in bone and drives differentiation of mesenchy-
mal stem cells to adipocytes rather than to osteoblasts [62]. 
TZD use is associated with increased fracture risk—the 
ADOPT study reported cumulative incidence of fractures of 
15.1% with rosiglitazone versus 7.3% with metformin [63]. 
Sodium–glucose cotransporter-2 (SGLT2) inhibitors have 
been associated with increased fracture risk [64], possibly 
through increased renal phosphate reabsorption leading to 
increased parathyroid hormone (PTH) and increased bone 
resorption [65]. Gut peptides such as GLP-2 decrease turn-
over in response to feeding, and there has been interest in 
the possible bone effects of GLP-1 analogues and dipepti-
dyl peptidase 4 (DPP-4) inhibitors in diabetes treatment. So 
far, there is no clear evidence of an effect on fracture risk 
[66]. Fracture risk is higher in people treated with insulin 
than with oral agents, but this may reflect insulin use as a 
marker of longer duration of disease, poorer control and 
more microvascular complications rather than a direct bio-
logical effect.
Fracture Risk Assessment and Osteoporosis 
Treatment in T2DM
Because BMD is increased in T2DM, and there are dis-
ease-specific risk factors such as microvascular disease and 
collagen glycation, standard fracture risk assessments using 
DXA and clinical risk factors (including FRAX) underesti-
mate fracture risk in T2DM [67]. Inadequate or inaccurate 
risk assessment is reflected in the observation that people 
with diabetes are less likely to be prescribed bisphospho-
nates than those without diabetes [68]. This may be partly 
due to underestimation of risk by assessment tools, but also 
because clinicians do not recognise that people with diabe-
tes are at risk of fracture, so do not assess their risk or treat.
Although the pathophysiology of fracture in T2DM dif-
fers from postmenopausal osteoporosis, (particularly in that 
bone turnover is low in T2DM), osteoporosis treatments do 
reduce fracture in T2DM. In post hoc analysis of the FIT 
alendronate and HORIZON zoledronic acid trial, fracture 
reduction was similar in participants with and without dia-
betes [69]. Teriparatide and sclerostin antibodies increase 
BMD in Zucker diabetic rats, but the rats’ bone phenotype 
is different from human T2DM, and there is not yet avail-
able information on these drugs in humans with T2DM [70, 
71].
Summary and Discussion
Obesity in adults is protective against some fractures, par-
ticularly hip fractures. However, some fractures, such as 
ankle and humerus are more common in obesity, and the 
prevalence of low-trauma fractures is similar in obese and 
non-obese women. BMD in obese people is higher at all 
sites, bone turnover is lower, and bone strength measures 
suggest that obesity is favourable for bone strength, but 
bone strength does not seem sufficiently increased to pro-
tect against all fractures. Therefore, explanations for the 
fracture pattern in obesity need to consider other factors 
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such as load-to-strength ratio, soft tissue padding, muscle 
function and falls. Finite element models incorporating 
patient-specific factors such as height, weight, soft tissue 
thickness and quantitative gait assessment with bone physi-
cal measurements may offer a route of investigation for 
these potential contributors.
There are many possible mechanisms acting on bone 
metabolism in obesity, such as adipokines and gut hor-
mones. Some of these are potential therapeutic targets 
for the treatment of osteoporosis in obese and non-obese 
people.
Type 2 diabetes is associated with increased BMD and 
lower bone turnover but increased overall risk of frac-
ture and hip fracture. Some of the mechanisms acting to 
increase BMD in obesity are likely to be relevant in T2DM, 
but the pathophysiology of bone fragility in T2DM is not 
yet clearly understood. Additional influence of AGEs on 
bone matrix and complications of diabetes are likely to 
contribute to the increased fracture risk, and AGE markers 
might be of value in further research and clinical assess-
ment. If glucose exposure and diabetes complications are 
major contributors, the most effective strategy to reduce 
fracture risk may be to improve glycaemic control. Fracture 
risk in T2DM is under-recognised, under-estimated and 
undertreated, but anti-resorptives do seem to be effective in 
fracture prevention. If diabetes bone disease is a low-turno-
ver state, it would be interesting to see whether it responds 
well to anabolic bone agents or whether the underlying 
pathology impairs the anabolic response.
As our populations become older and more obese, 
understanding the interactions of obesity, T2DM and frac-
ture is becoming a pressing need to reduce the societal and 
individual costs of fracture.
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